As listed on ClinicalTrials.gov
A Randomized, Phase II, Open-Label Study of Supervised Aerobic and Resistance Exercise Concurrent With Adjuvant Chemotherapy in Women With Stage I–III Breast Cancer
Participants will be randomized 1:1 to a supervised exercise intervention (3 sessions/week, 150 min/week moderate-to-vigorous intensity) or usual care for the duration of adjuvant chemotherapy. The primary endpoint is relative dose intensity (RDI ≥ 85%). Secondary endpoints include patient-reported fatigue (FACIT-F), VO₂peak, and chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20). Eligible participants must have an ECOG performance status of 0–1 and no contraindications to exercise per ACSM guidelines.
NCT90000002